Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System - Takeaways - MDSpire

Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System

  • By

  • David P Bui

  • Denise M Hynes

  • Edwin Wong

  • Robert Vergun

  • Lei Yan

  • Yuli Li

  • Nallakkandi Rajeevan

  • Kristin Berry

  • Hung-Mo Lin

  • Yuan Huang

  • Diana J Govier

  • Mihaela Aslan

  • George Ioannou

  • Kristina L Bajema

  • September 24, 2025

  • 0 min

Share

  • 1

    The budget impact analysis of nirmatrelvir-ritonavir (NR) for COVID-19 treatment in the Veterans Health Administration (VHA) was conducted for eligible Veterans.

  • 2

    Among 138,261 treatment-eligible Veterans, 18% were prescribed NR, leading to a healthcare cost reduction of $20 million but an overall budget increase of $122 million.

  • 3

    Targeted treatment of high-risk patients achieved healthcare savings of $17 million, while increasing total budget costs by $3 million.

  • 4

    The high purchasing cost of NR, priced at $1,031 per course, likely exceeds the savings from reduced healthcare utilization.

  • 5

    Price reductions for NR are essential for it to be a financially viable treatment option within healthcare systems.

Original Source(s)

Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System

  • by David P Bui, Denise M Hynes, Edwin Wong, Robert Vergun, Lei Yan, Yuli Li, Nallakkandi Rajeevan, Kristin Berry, Hung-Mo Lin, Yuan Huang, Diana J Govier, Mihaela Aslan, George Ioannou, Kristina L Bajema

  • September 24, 2025

Related Content

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

Cough Audio Recognition for Early Detection of Respiratory Diseases: Algorithm Development and Validation Study